Roche’s Kadcyla Beats Herceptin in Delaying Cancer Progression
This article is for subscribers only.
Roche Holding AG’s Kadcyla almost doubled the delay in disease progression for advanced breast cancer patients compared with those whose doctors were free to choose any other treatment, a study showed.
In a trial among 602 patients whose cancer was inoperable or had recurred after treatment with drugs including Roche’s Herceptin and GlaxoSmithKline Plc’s Tykerb, those receiving Kadcyla lived a median of 6.2 months without their disease progressing, compared with 3.3 months for those whose doctors chose a different therapy, according to data to be presented at a cancer conference in Amsterdam today.